Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX42 in advanced/metastatic solid tumors and NSCLC
NCT06210815Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Mar 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HLX42 in solid tumor and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 3 weeks and Maximum Tolerated Dose at 3 weeks. Started Mar 2024; status: recruiting.
02
Drugs
HLX42
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06210815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210815.